Sinequan: Uses, dosage, side effects, warnings & patient reviews

What is Sinequan (Doxepin)?

Sinequan is the brand name for the generic drug doxepin hydrochloride. It belongs to the class of medications known as tricyclic antidepressants (TCAs). It is primarily prescribed for the treatment of depression and anxiety disorders.

Its mechanism of action involves inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin in the central nervous system. This activity is believed to contribute to its antidepressant and anxiolytic effects. Sinequan also has potent antihistaminic properties, which account for its significant sedative effect.

For more information on treatments for these conditions, see our resource pages on depression and anxiety.

Forms and Availability

Sinequan is available as oral capsules in various strengths, including 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. It is also available in a generic form as doxepin capsules. This medication requires a prescription and is not available over-the-counter.

How to Take Sinequan

Administration of Sinequan must be precisely followed as directed by a prescribing physician. Deviations can affect safety and efficacy.

Administration Guidelines

Sinequan capsules should be swallowed whole with a full glass of water. They are typically taken one to three times daily. To minimize daytime drowsiness, a physician may direct that the total daily dose be taken once at bedtime.

The medication may be taken with or without food. Taking it with food can help reduce potential stomach upset.

Dosage Initiation and Adjustment

Treatment with Sinequan usually begins at a low dose, which is gradually increased based on the patient’s clinical response and tolerance to side effects. Dose adjustments should only be made under the supervision of the prescribing doctor.

It is important not to stop taking Sinequan abruptly, as this can lead to withdrawal symptoms such as nausea, headache, and malaise. Discontinuation should be managed through a gradual dose reduction under medical guidance.

Duration of Therapy

The full therapeutic effect for depression or anxiety may take several weeks to become apparent. Sinequan should be taken for the duration prescribed, even if symptoms begin to improve.

Side Effects of Sinequan

Sinequan can cause a range of side effects due to its pharmacological activity. The likelihood and severity of side effects often correlate with the dosage.

What is Sinequan Used For?

Sinequan is indicated for the treatment of specific psychiatric conditions. Its use is determined by a physician following a clinical diagnosis.

FDA-Approved Uses

• Depression: Sinequan is indicated for the treatment of psychoneurotic patients with depression and/or anxiety.
• Anxiety Disorders: It is approved for the treatment of anxiety associated with psychoneurosis and for depressive symptoms accompanying alcoholism or organic disease.

Its efficacy in treating depression and anxiety disorders is well-established, though it is typically not a first-line agent due to its side effect profile.

Other Clinical Uses

Under physician direction, Sinequan may be used for conditions outside its formal FDA labeling (off-label).

• Insomnia: At very low doses (e.g., 3-6 mg), doxepin is prescribed specifically for sleep maintenance insomnia due to its potent histamine-blocking effects. This is distinct from the higher doses used for depression.
• Chronic Pruritus: Its antihistaminic properties make it useful for managing severe, chronic itching. For related skin care information, see skincare.

For more on sleep-related medications, visit our sleep aids category.

Important Safety Concerns and Considerations

Several specific risks are associated with Sinequan therapy and require vigilant management.

Suicidality and Antidepressant Use

Sinequan carries a Black Box Warning, the FDA’s strongest safety alert. Antidepressants may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) during the initial months of treatment. Patients of all ages started on therapy should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior.

Cardiovascular Effects

Sinequan can cause orthostatic hypotension (a sudden drop in blood pressure upon standing), tachycardia, and QT interval prolongation on an electrocardiogram. It is contraindicated in patients during the acute recovery phase after a myocardial infarction. It should be used with extreme caution in patients with a history of cardiovascular disease.

Anticholinergic Effects

Due to its strong anticholinergic properties, Sinequan is contraindicated in patients with untreated narrow-angle glaucoma or a tendency toward urinary retention. It can increase intraocular pressure; caution is advised in patients using medications for glaucoma, such as prostaglandin analogs. It can also exacerbate symptoms in men with benign prostatic hyperplasia; see a guide to BPH medications.

Narrow Therapeutic Index and Overdose

Like other TCAs, Sinequan has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is small. Overdose is particularly dangerous and can be fatal, presenting with symptoms of severe CNS depression, cardiac arrhythmias, and hypotension. Medication must be stored securely. For critical information, see our article on accidental medicine overdose.

Critical Warnings for Sinequan Use

Monoamine Oxidase Inhibitors (MAOIs)

Sinequan is contraindicated in patients who are currently taking MAOIs or who have taken them within the preceding 14 days. Concomitant use can precipitate hyperpyretic crises, severe convulsions, and death.

Glaucoma and Urinary Retention

As noted, use is contraindicated in patients with untreated narrow-angle glaucoma or urinary retention due to strong anticholinergic effects. Pre-existing conditions should be treated prior to initiation.

Seizure Disorders

Sinequan may lower the seizure threshold. It should be used with extreme caution in patients with a history of seizures or conditions that predispose to them.

Hepatic Impairment

Because Sinequan is extensively metabolized by the liver, patients with hepatic impairment may develop elevated plasma levels and require significantly lower doses.

Discontinuation Syndrome

Abrupt discontinuation after prolonged use can lead to withdrawal symptoms such as nausea, headache, malaise, and sleep disturbance. Therapy should be tapered gradually under medical supervision.

Sinequan Dosage Information

Dosage is highly individualized and must be determined by a physician based on diagnosis, patient response, and tolerance to side effects.

Important Administration Notes

• Geriatric/Debilitated Patients: Lower initial doses (e.g., 25 mg to 50 mg daily) are recommended, with gradual increases.
• Maintenance Therapy: After a satisfactory response is obtained, the dose may be reduced to the lowest effective level.
• Dose Adjustments: Any changes should be made at intervals of several days to a week to allow for clinical assessment.

Drug Interactions with Sinequan

Sinequan interacts with many medications. This is not a complete list. Always inform your healthcare provider of all products you use.

Note: Doxepin has a pharmacological profile similar to other sedating antihistamines/anxiolytics, such as hydroxyzine (Atarax). Their effects can be additive.

Additional Information

Storage and Handling

Store Sinequan capsules at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly closed container. Protect from light and moisture. Keep all medications out of the reach of children and pets, as even a small ingestion can be extremely dangerous. For critical safety information, refer to our article on accidental medicine overdose.

Drug Class and Comparison

Sinequan (doxepin) is a tricyclic antidepressant, specifically a tertiary amine TCA. It shares a similar sedative and anticholinergic profile with other TCAs like amitriptyline. Its potent antihistaminic effect is comparable to medications like hydroxyzine (Atarax), which are used for anxiety and pruritus. The choice of agent depends on the individual’s diagnosis, medical history, and side effect tolerance.

Reporting Side Effects

If you experience a suspected side effect, report it to your prescribing physician. You are also encouraged to report adverse events directly to the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch. Reporting helps improve overall drug safety knowledge.

References and Medical Sources

1. U.S. Food and Drug Administration (FDA). Sinequan (doxepin HCl) Capsules Prescribing Information. [Revised 2011]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016798s054,017516s023lbl.pdf
2. MedlinePlus. Doxepin. U.S. National Library of Medicine; [Updated 2021]. https://medlineplus.gov/druginfo/meds/a682390.html
3. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023.
4. Drugs.com. Doxepin Professional Monograph. Drugs.com; [Updated 2024]. https://www.drugs.com/monograph/doxepin.html

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.